InspireMD (NYSE:NSPR - Get Free Report) had its price target dropped by stock analysts at Piper Sandler from $4.50 to $4.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Piper Sandler's price objective would indicate a potential upside of 58.10% from the stock's current price.
Separately, StockNews.com initiated coverage on shares of InspireMD in a research report on Monday, May 5th. They set a "sell" rating on the stock.
Get Our Latest Analysis on InspireMD
InspireMD Stock Down 2.7%
NSPR stock traded down $0.07 during trading on Monday, hitting $2.53. 26,466 shares of the company's stock traded hands, compared to its average volume of 36,923. InspireMD has a 52 week low of $2.07 and a 52 week high of $3.80. The stock has a fifty day moving average price of $2.66 and a two-hundred day moving average price of $2.74. The stock has a market capitalization of $77.51 million, a price-to-earnings ratio of -3.37 and a beta of 0.62.
Institutional Investors Weigh In On InspireMD
Hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC acquired a new stake in shares of InspireMD during the 4th quarter worth approximately $27,000. Essex Investment Management Co. LLC purchased a new position in shares of InspireMD during the fourth quarter worth approximately $191,000. Affiance Financial LLC boosted its holdings in InspireMD by 2.9% during the 4th quarter. Affiance Financial LLC now owns 189,122 shares of the company's stock valued at $497,000 after acquiring an additional 5,376 shares during the period. Legato Capital Management LLC purchased a new stake in InspireMD in the fourth quarter worth $47,000. Finally, XTX Topco Ltd purchased a new stake in shares of InspireMD in the 1st quarter worth approximately $38,000. Institutional investors and hedge funds own 44.78% of the company's stock.
About InspireMD
(
Get Free Report)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider InspireMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.
While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
